I think an ORTX run to 4.25-4.50 is possible its currently priced at 2.99 aftermarket its been holding between 3.00 and 2.95 after its 3 month downtrend. this current plateau could signify the breakthrough to 4.25 or higher. you also saw multiple price spikes with this company during covid lockdown periods. to be clear this company has zero involvment with covid research but during lockdowns you saw retail investors eager to get in on the biopharma rush as those were some of the first to recover from the crash. with impending lockdowns due to delta variant i would not be surprised to see a similar trend repeat.
not a professional investor just between current price plateau, this biopharma craze, and previous 3 quarters increasing in profitability i believe run could be primed.
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.